Patents by Inventor Lars Henning ENGELHOLM

Lars Henning ENGELHOLM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
    Publication number: 20240131179
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Application
    Filed: October 11, 2023
    Publication date: April 25, 2024
    Inventors: Christoffer NIELSEN, Niels BEHRENDT, Lars Henning ENGELHOLM
  • Antibody-drug conjugates targeting uPARAP
    Patent number: 11819552
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 21, 2023
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
  • ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
    Publication number: 20210162062
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Inventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
  • Antibody-drug conjugates targeting uPARAP
    Patent number: 10940213
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 9, 2021
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
  • ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
    Publication number: 20190046658
    Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 14, 2019
    Inventors: Christoffer NIELSEN, Niels BEHRENDT, Lars Henning ENGELHOLM